Skip to main content

Table 2 Unadjusted and adjusted odds ratios related to positive HCV status at registration

From: Prevalence, risk factors, treatment uptake and treatment outcome of hepatitis C virus in people who inject drugs at the needle and syringe program in Uppsala, Sweden

 

Simple univariate regression, N = 450a

Multiple univariate regression, N = 391b

Odds ratio (95% CI)

p value

Odds ratio (95% CI)

p value

Gender

    

 Female

Reference

 

Reference

 

 Male

1.045 (0.684–1.598)

0.838

0.774 (0.463–1.293)

0.327

Age at registration

1.012 (0.995–1.028)

0.165

1.025 (1.004–1.046)

0.018

Age of debut of drug use

0.927 (0.879–0.977)

0.005

0.975 (0.916–1.037)

0.423

Age of debut of injection drug use

0.956 (0.931–0.982)

< 0.001

0.963 (0.932–0.996)

0.026

Total number of NSP visits

1.007 (1.003–1.011)

0.001

1.005 (1.001–1.009)

0.027

Level of education

    

 Upper secondary/Vocational/University

Reference

 

Reference

 

 Partial elementary/Elementary

2.216 (1.510–3.251)

< 0.001

1.829 (1.185–2.821)

0.006

Living situation the past 3 months

    

 All other

Reference

 

Reference

 

 Homeless/Shelter

1.377 (0.948–2.000)

0.093

1.348 (0.879–2.067)

0.172

Employment the past 3 months

    

 All other

Reference

 

Reference

 

 Unemployed/Sick/Activity compensation

1.320 (0.873–1.996)

0.188

1.337 (0.832–2.149)

0.230

Primary drug used the past 12 months

    

 Other

Reference

 

Reference

 

 Amphetamine

0.998 (0.607–1.643)

0.995

0.642 (0.870–0.484)

0.642

 Heroin

0.996 (0.555–1.785)

0.988

0.973 (0.503–1.882)

0. 935

Shared needle, syringe or paraphernalia past month

    

 No

Reference

 

Reference

 

 Yes

1.425 (0.977–2.078)

0.066

1.233 (0.798–1.904)

0.345

HBV status at registration (anti-Hbc)

    

 Negative

Reference

 

Reference

 

 Positive

0.271 (0.030–2.442)

0.244

0.199 (0.021–1.887)

0.160

  1. aMissing data (n): Age of debut of drug use (15), age of debut of injection drug use (22), level of education (13), living situation the past 3 months (3), employment the past 3 months (8), primary drug used the past 12 months (3), shared needle, syringe or paraphernalia past month (9), HBV status (18)
  2. bOnly performed on patients with no missing data in any category
  3. Underlined numbers representing a p value < 0.05